Cargando…
Denosumab in Giant Cell Tumor of Bone: Current Status and Pitfalls
Denosumab is a monoclonal antibody against RANK ligand for treatment of giant cell tumor of bone (GCTB). Clinical trials and case series have demonstrated that denosumab is relevant to beneficial tumor response and surgical down-staging in patients of GCTB. However, these trials or case series have...
Autores principales: | Li, Hengyuan, Gao, Junjie, Gao, Youshui, Lin, Nong, Zheng, Minghao, Ye, Zhaoming |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7567019/ https://www.ncbi.nlm.nih.gov/pubmed/33123484 http://dx.doi.org/10.3389/fonc.2020.580605 |
Ejemplares similares
-
Current status and unanswered questions on the use of Denosumab in giant cell tumor of bone
por: Gaston, Czar Louie, et al.
Publicado: (2016) -
Autologous costal chondral transplantation and costa-derived chondrocyte implantation: emerging surgical techniques
por: Gao, Youshui, et al.
Publicado: (2019) -
Current comprehensive understanding of denosumab (the RANKL neutralizing antibody) in the treatment of bone metastasis of malignant tumors, including pharmacological mechanism and clinical trials
por: Lu, Junjie, et al.
Publicado: (2023) -
Rechallenge of denosumab in advanced giant cell tumor of the bone after atypical femur fracture: A case report and review of literature
por: Nasca, Vincenzo, et al.
Publicado: (2022) -
Case Report: Unresectable pulmonary metastases of a giant cell tumor of bone treated with denosumab: a case report and review of literature
por: Miwa, Shinji, et al.
Publicado: (2023)